These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 19414323)

  • 21. CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion.
    Qin XJ; Shi HZ; Deng JM; Liang QL; Jiang J; Ye ZJ
    Clin Cancer Res; 2009 Apr; 15(7):2231-7. PubMed ID: 19318474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased frequency of CD4+CD25(high)FoxP3+ regulatory T cells in patients with hepatocellular carcinoma.
    Feng X; Li B; Ye H; Long D
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):309-14. PubMed ID: 21633918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decrease of CD4(+)CD25(+) regulatory T cells and TGF-beta at early immune reconstitution is associated to the onset and severity of graft-versus-host disease following allogeneic haematogenesis stem cell transplantation.
    Li Q; Zhai Z; Xu X; Shen Y; Zhang A; Sun Z; Liu H; Geng L; Wang Y
    Leuk Res; 2010 Sep; 34(9):1158-68. PubMed ID: 20409584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
    Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
    Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
    Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
    Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autocrine vascular endothelial growth factor/vascular endothelial growth factor receptor-2 growth pathway represents a cyclooxygenase-2-independent target for the cyclooxygenase-2 inhibitor NS-398 in colon cancer cells.
    Kim SJ; Seo JH; Lee YJ; Yoon JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Oncology; 2005; 68(2-3):204-11. PubMed ID: 16015035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The frequency, phenotypes and functions of CD4+ CD25+ regulatory T cells in hepatocellular carcinoma patients].
    Zhang HH; Fei R; Mei MH; Liao WJ; Wang XY; Cong X; Qin LL; Ji Y; Wang SX; Wei L; Chen HS
    Zhonghua Gan Zang Bing Za Zhi; 2007 Apr; 15(4):266-72. PubMed ID: 17456313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma.
    Strizzi L; Catalano A; Vianale G; Orecchia S; Casalini A; Tassi G; Puntoni R; Mutti L; Procopio A
    J Pathol; 2001 Apr; 193(4):468-75. PubMed ID: 11276005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.
    Morera Y; Bequet-Romero M; Ayala M; Lamdán H; Agger EM; Andersen P; Gavilondo JV
    Angiogenesis; 2008; 11(4):381-93. PubMed ID: 19034678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
    Karp JE; Gojo I; Pili R; Gocke CD; Greer J; Guo C; Qian D; Morris L; Tidwell M; Chen H; Zwiebel J
    Clin Cancer Res; 2004 Jun; 10(11):3577-85. PubMed ID: 15173063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of inducible CD4+CD25+Foxp3+ regulatory T lymphocytes by porcine reproductive and respiratory syndrome virus (PRRSV).
    Wongyanin P; Buranapraditkun S; Chokeshai-Usaha K; Thanawonguwech R; Suradhat S
    Vet Immunol Immunopathol; 2010 Feb; 133(2-4):170-82. PubMed ID: 19709757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increase of regulatory T cells in the peripheral blood of cancer patients.
    Wolf AM; Wolf D; Steurer M; Gastl G; Gunsilius E; Grubeck-Loebenstein B
    Clin Cancer Res; 2003 Feb; 9(2):606-12. PubMed ID: 12576425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerogenic dendritic cells induce CD4+CD25hiFoxp3+ regulatory T cell differentiation from CD4+CD25-/loFoxp3- effector T cells.
    Huang H; Dawicki W; Zhang X; Town J; Gordon JR
    J Immunol; 2010 Nov; 185(9):5003-10. PubMed ID: 20870943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N; Hillan KJ; Novotny W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete remission of psoriasis following bevacizumab therapy for colon cancer.
    Akman A; Yilmaz E; Mutlu H; Ozdogan M
    Clin Exp Dermatol; 2009 Jul; 34(5):e202-4. PubMed ID: 19077094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK; Piao Y; de Groot JF
    Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab.
    Mahajan D; Miller C; Hirose K; McCullough A; Yerian L
    J Hepatol; 2008 Nov; 49(5):867-70. PubMed ID: 18814928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
    Li Q; Yano S; Ogino H; Wang W; Uehara H; Nishioka Y; Sone S
    Clin Cancer Res; 2007 Oct; 13(19):5918-25. PubMed ID: 17908988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions.
    Duysinx BC; Corhay JL; Hubin L; Nguyen D; Henket M; Louis R
    Respir Med; 2008 Dec; 102(12):1708-14. PubMed ID: 18760578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.